Hicklin
Daniel J. Hicklin, Upper Montclair, NJ US
Patent application number | Description | Published |
---|---|---|
20110269186 | ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 - Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti-VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies. | 11-03-2011 |
Daniel J. Hicklin, Glen Ridge, NJ US
Patent application number | Description | Published |
---|---|---|
20080311121 | ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY - The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin. ( | 12-18-2008 |
20080317750 | ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY - The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. | 12-25-2008 |
20090060909 | ANTIBODY ANTAGONISTS OF VE-CADHERIN WITHOUT ADVERSE EFFECTS ON VASCULAR PERMEABILITY - The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. | 03-05-2009 |
Daniel J. Hicklin, Montclair, NJ US
Patent application number | Description | Published |
---|---|---|
20100028347 | ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 - Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti -VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies. | 02-04-2010 |
20150218274 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF - Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders. | 08-06-2015 |
Danny J. Hicklin, Montclair, NJ US
Patent application number | Description | Published |
---|---|---|
20120208844 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF - The present invention provides a compound of Formula (1) as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. | 08-16-2012 |
20140336222 | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF - The present invention provides a compound of Formula 1 | 11-13-2014 |
Jack S. Hicklin, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20150359772 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE - Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction. | 12-17-2015 |
Mark Hicklin, Derby GB
Patent application number | Description | Published |
---|---|---|
20150114005 | GAS TURBINE ENGINE - A gas turbine engine having a fan and a bypass duct for discharging airflow from the fan to generate engine thrust. The bypass duct includes a first component and a second component each having a gas washed surface, the first component being positioned adjacent the second component with a gap therebetween. A sealing strip is positioned in the gap between the first component and the second component distal to the gas washed surfaces of the first and second components. A sealant is positioned between the first and second component proximal to the gas washed surfaces of the first and second components, so as to seal the gap between the first component and the second component from airflow through the bypass duct. | 04-30-2015 |
Robert Hicklin, Leicestershire GB
Patent application number | Description | Published |
---|---|---|
20110262647 | TREATMENT OF TEXTILE MATERIALS - The present invention provides a method for treating textile material to confer flame retardant properties, the method comprising the steps of impregnating the material with an aqueous solution of a treatment agent which is a poly (hydroxyorgano) phosphonium compound; drying the impregnated material; curing the dried impregnated material with ammonia to produce a cured, water-insoluble polymer which is mechanically fixed within the fibres of the material; oxidising the cured polymer to convert trivalent phosphorus to pentavalent phosphorus; and washing and drying the material; wherein one or both of steps (d) and (e) result in the co-production of an aqueous effluent; and wherein the conditions are controlled such that the atomic ratio of N:P present on the material increases during step (c) by 0.8 or more. | 10-27-2011 |
20120122361 | Treatment of Textile Materials - The invention provides a method for the treatment of textile material having a threat face and a rear face, so as to obtain a treated material that is flame retardant but also provides protection from molten metal splash on the threat face, the method comprising: a) providing a textile material that comprises cotton and/or wool, and that has a weight of 250g/m | 05-17-2012 |